Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.
Multiple Myeloma
NK cells
PD-1
cell Therapy and Immunotherapy
cytotoxicity
daratumumab
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
29 12 2020
29 12 2020
Historique:
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
29
7
2021
Statut:
epublish
Résumé
In this study we evaluated the potential of expanded NK cells (eNKs) from two sources combined with the mAbs daratumumab and pembrolizumab to target primary multiple myeloma (MM) cells
Identifiants
pubmed: 33457074
doi: 10.1080/2162402X.2020.1853314
pii: 1853314
pmc: PMC7781838
doi:
Substances chimiques
Antibodies, Monoclonal
0
daratumumab
4Z63YK6E0E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1853314Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Theranostics. 2018 Jun 14;8(14):3856-3869
pubmed: 30083264
Neoplasma. 2018 Sep 19;65(5):720-729
pubmed: 29940772
Eur J Cell Biol. 2014 Jan-Feb;93(1-2):49-54
pubmed: 24629838
Oncotarget. 2016 Nov 8;7(45):72961-72977
pubmed: 27662664
N Engl J Med. 2015 Sep 24;373(13):1207-19
pubmed: 26308596
Haematologica. 2017 Mar;102(3):423-432
pubmed: 28082344
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Br J Haematol. 2008 Dec;143(5):641-53
pubmed: 18950462
Cancer Treat Rev. 2018 Nov;70:199-208
pubmed: 30245231
Front Immunol. 2017 Mar 23;8:329
pubmed: 28386260
Front Immunol. 2016 Oct 27;7:454
pubmed: 27833611
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
J Immunother. 2015 Jan;38(1):24-36
pubmed: 25415285
Front Immunol. 2020 Jan 09;10:3010
pubmed: 31998304
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Front Immunol. 2018 Nov 16;9:2431
pubmed: 30505301
Int J Hematol. 2018 Mar;107(3):278-285
pubmed: 29368256
Oncoimmunology. 2015 Jan 09;4(3):e991613
pubmed: 25949911
Crit Rev Oncol Hematol. 2017 Mar;111:87-93
pubmed: 28259300
EBioMedicine. 2015 Aug 13;2(10):1364-76
pubmed: 26629531
Clin Cancer Res. 2018 Aug 15;24(16):4006-4017
pubmed: 29666301
Cancer Immunol Immunother. 2020 Mar;69(3):421-434
pubmed: 31919623
Nat Immunol. 2012 Dec;13(12):1129-32
pubmed: 23160205
Oncoimmunology. 2015 Mar 2;4(6):e1008824
pubmed: 26155422
Front Cell Dev Biol. 2019 Apr 16;7:50
pubmed: 31041312
Leukemia. 2015 Oct;29(10):2110-3
pubmed: 25778100
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Tissue Antigens. 2012 Aug;80(2):184-7
pubmed: 22708664
J Clin Oncol. 2010 Feb 20;28(6):955-9
pubmed: 20085940
Cancer Sci. 2020 Oct 16;:
pubmed: 33064914
Front Immunol. 2020 Jan 13;10:3026
pubmed: 31998309
Front Immunol. 2017 Nov 07;8:1444
pubmed: 29163516
Front Immunol. 2018 Sep 26;9:2204
pubmed: 30319648
Haematologica. 2011 Feb;96(2):284-90
pubmed: 21109694
Leukemia. 2009 Mar;23(3):492-500
pubmed: 19151783
Cancer Res. 2018 May 15;78(10):2449-2456
pubmed: 29703720
Blood. 2007 Jul 1;110(1):296-304
pubmed: 17363736
Oncoimmunology. 2018 Feb 12;7(4):e1395123
pubmed: 29632716
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Oncoimmunology. 2019 Apr 13;8(7):1599636
pubmed: 31143521
Leukemia. 2014 Apr;28(4):917-27
pubmed: 24067492
Blood Cancer J. 2015 Mar 06;5:e285
pubmed: 25747678
Oncoimmunology. 2016 Nov 22;5(12):e1250051
pubmed: 28123890
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Front Immunol. 2018 Nov 05;9:2551
pubmed: 30455698
Sci Rep. 2020 Nov 10;10(1):19398
pubmed: 33173077
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Biochem Cell Biol. 2014 Apr;49:42-52
pubmed: 24440757
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373